Camarasa Xavier, Lopez-Martinez Elena, Duboc Annik, Khazaal Yasser, Zullino Daniele Fabio
Hôpital Psychiatrique Cantonal de Marsens, Switzerland.
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):165-8. doi: 10.1016/j.pnpbp.2004.10.002. Epub 2004 Nov 19.
Acting pharmacologically on different transmitter systems has been suggested to have some advantages in patients with substance abuse and may possibly address a larger spectrum of symptoms. One major drawback of using antidepressants addressing several neurotransmitters is that the relative activities on the different neurotransmitters cannot individually be adjusted. Combining antidepressants targeting different neurotransmitter systems may allow adapting the effect on each neurotransmitter system corresponding to patients' response and tolerance. Three cases of patients presenting a substance use disorder with comorbid major depression episodes are presented, who were treated with a reboxetine/escitalopram combination and who showed a rapid response of their depressive syndrome.
对不同递质系统进行药理作用已被认为对物质滥用患者有一些优势，并且可能解决更广泛的症状。使用针对多种神经递质的抗抑郁药的一个主要缺点是，无法单独调整对不同神经递质的相对活性。联合使用针对不同神经递质系统的抗抑郁药可能允许根据患者的反应和耐受性来调整对每个神经递质系统的作用。本文介绍了3例患有物质使用障碍合并重度抑郁发作的患者，他们接受了瑞波西汀/艾司西酞普兰联合治疗，且其抑郁综合征迅速得到缓解。
